HIGHLIGHTS
- who: Yardley, and PA, from the OptiNose Inc have published the paper: OptiNose Inc., Yardley, PA , in the Journal: (JOURNAL) of October/22,/2022
SUMMARY
Late Breaking Abstract. Late Breaking Abstract Conclusions. Ceftobiprole is non-inferior to daptomycin for overall success in patients with complicated SAB. All-cause mortality, microbiological eradication rates and new SAB complications were similar between treatment groups. @@
ACRONYMS
LAY DEFINITIONS
Licence: cc-by
Site reference:
If you want to have access to all the content you need to log in! Thanks :)
If you don't have an account, you can create one here. 